“[…] DPE analysis may have an important role in improving the diagnosis and mana...
Breast cancer is the most common cancer to affect women worldwide. According to ...
It feels like a classical paradox: How do you see the invisible? But for modern ...
People with autism spectrum disorder can be classified into four distinct subtyp...
After an FDA rejection and a failed collaboration, Akebia Therapeutics is contin...
The FDA approved an anti-inflammatory treatment for treating COVID-19 despite a ...
SynKIR-110 is an investigational drug to treat mesothelin-expressing mesotheliom...
The agreement will provide the company with additional capital for its growth tr...
Ginkgo will also receive StrideBio's existing library of capsids optimised for p...
LIVMARLI showed maintenance of treatment effect with sustained decrease in serum...
GRIA disorder is a family of rare genetic diseases triggered by mutations in the...
Everest’s NDA for Nefecon in China is anticipated to receive clearance by the se...
Biotheryx will receive up to $347m in potential future regulatory and commercial...
Shanghai Henlius Biotech, Accord’s business partner, originally developed HLX02.
After more than a decade, the FDA has updated its guidance for patient-focused d...
The UK’s MHRA gave a green light to the company to start a Phase IIb trial with ...
